Overview
Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive form of lung cancer with limited treatment options. While combination immunotherapy and platinum chemotherapy has become the standard first-line treatment, patients frequently experience recurrence. Second-line treatment decisions depend on whether cancer returns quickly ("platinum-refractory") or slowly ("platinum-sensitive") after initial chemotherapy, but treatment patterns in the post-immunotherapy era remain uncertain.
This study used Flatiron Health’s US SCLC Panoramic Database, inclusive of more than 27,400 patients with SCLC, and analyzed real-world treatment patterns and outcomes for nearly 900 patients with platinum-sensitive ES-SCLC who received second-line therapy. Among platinum-sensitive patients, 48% were rechallenged with platinum chemotherapy, and 41% of those also continued immunotherapy. Researchers compared outcomes between patients who received platinum rechallenge with or without continued immunotherapy.
Patients with platinum-sensitive disease had better progression-free and overall survival compared to platinum-refractory patients (median survival of 11.2 months versus 4.7 months). However for patients with platinum sensitive disease, continuing immunotherapy with platinum rechallenge did not improve response rates, progression-free survival, or overall survival compared to platinum rechallenge alone.
Why this matters
These findings suggest that continuing immunotherapy beyond first-line treatment may not provide additional benefit in platinum-sensitive ES-SCLC. The results highlight the need for prospective studies to better guide treatment decisions after immunotherapy failure and help oncologists make more informed, individualized decisions for each patient's unique situation.